FDA Delay Forces Small Biotech Company to Shut Down Operations

Kezar Life Sciences, a small biotech company developing autoimmune hepatitis treatment, was forced to wind down operations after the FDA abruptly canceled a scheduled October 2025 meeting without explanation and did not reach a clinical trial agreement until February 2026. The four-month delay proved fatal as investors lost confidence and withdrew support, leaving the company unable to continue. Meanwhile, the obesity treatment market is experiencing rapid expansion with Novo Nordisk's oral Wegovy on the market since January 2026 and Eli Lilly's newly approved Foundayo joining in April 2026. All seven obesity specialists interviewed have begun prescribing oral Wegovy, primarily to first-time GLP-1 patients seeking lower cost and greater convenience, in a market projected to exceed $100 billion annually within the next decade.

FDA delay leads to Kezar Life Sciences shutdown

• ▪Kezar Life Sciences reached an agreement with the U.S. Food and Drug Administration in February 2026 on a plan for a clinical trial for autoimmune hepatitis treatment
• ▪Kezar Life Sciences investors wanted out after the U.S. Food and Drug Administration meeting cancellation left the company's path forward unclear
• ▪The U.S. Food and Drug Administration had scheduled a meeting with Kezar Life Sciences to discuss trial design for October 2025
• ▪The U.S. Food and Drug Administration abruptly canceled the October 2025 meeting with Kezar Life Sciences without explanation
• ▪The February 2026 agreement between Kezar Life Sciences and the U.S. Food and Drug Administration came four months too late for the company
• ▪Kezar Life Sciences is a small biotech company developing a treatment for autoimmune hepatitis

Oral weight loss drug market expansion and patient preferences

• ▪Eli Lilly's newly approved oral weight loss drug Foundayo joins the market in the week of April 6, 2026
• ▪Three of the seven obesity specialist doctors interviewed have prescribed oral Wegovy to about 10% of their patients
• ▪Most patients receiving oral Wegovy prescriptions are taking a GLP-1 drug for the first time rather than switching from injectables
• ▪The obesity treatment market is projected to exceed $100 billion annually within the next decade
• ▪Novo Nordisk's oral Wegovy pill has been on the market since January 2026

Perspective of Kezar Life Sciences

• ▪Kezar Life Sciences could not sustain operations during the four-month delay between the canceled October 2025 meeting and the February 2026 agreement
• ▪The U.S. Food and Drug Administration's unexplained cancellation of the October 2025 meeting left Kezar Life Sciences' path forward unclear

Perspective of Obesity specialist doctors

• ▪Obesity specialist doctors are primarily prescribing oral Wegovy to patients starting GLP-1 treatment for the first time rather than switching existing patients from injectables

Perspective of Novo Nordisk and Eli Lilly

• ▪Novo Nordisk and Eli Lilly are positioning oral weight loss medications to compete in a market projected to exceed $100 billion annually within the next decade
• ▪Eli Lilly's Foundayo approval in April 2026 creates direct competition with Novo Nordisk's oral Wegovy in the oral weight loss medication market